SCHEMBL8768829

SCHEMBL8768829

CC(=O)Nc1ccc(C(=O)Nc2ccc(-c3nc4cc(NC(=O)c5ccc(NC(C)=O)cc5)ccc4[nH]3)cc2)cc1

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPSE Q9Y251 2/20 0.67
MMP2 P08253 5/20 0.62
MMP9 P14780 5/20 0.62
MMP8 P22894 5/20 0.62
MMP13 P45452 5/20 0.62
MEN1 O00255 5/20 0.60
KMT2A Q03164 5/20 0.60
KDM4E B2RXH2 5/20 0.60
ALDH1A1 P00352 4/20 0.60
HPGD P15428 3/20 0.60
TP53 P04637 2/20 0.60
HSD17B10 Q99714 2/20 0.60
TDP1 Q9NUW8 1/20 0.60
NPC1 O15118 3/20 0.59
RAB9A P51151 3/20 0.59
GAA P10253 1/20 0.58
MAPT P10636 3/20 0.57
ATM Q13315 2/20 0.57
POLB P06746 2/20 0.57
THRB P10828 1/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14381672 0.95 HPSE (0.69) HPSEMMP2MMP9MMP8MMP13
SCHEMBL26754497 0.95 HPSE (0.62) HPSEMMP2MMP9MMP8MMP13
SCHEMBL14381714 0.92 KDM4E (0.57) HPSEMMP2MMP9MMP8MMP13
SCHEMBL20982455 0.91 ALDH1A1 (0.67) HPSEMEN1KMT2AKDM4EALDH1A1
SCHEMBL30667663 0.90 ALDH1A1 (0.72) HPSEMMP2MMP9MMP8MMP13
SCHEMBL12296724 0.90 ALDH1A1 (0.72) HPSEMMP2MMP9MMP8MMP13
SCHEMBL20982497 0.90 ALDH1A1 (0.66) HPSEMEN1KMT2AKDM4EALDH1A1
SCHEMBL1664867 0.89 ALDH1A1 (0.59) HPSEMMP2MMP9MMP8MMP13
SCHEMBL8768340 0.88 MMP2 (0.77) HPSEMMP2MMP9MMP8MMP13
SCHEMBL14684216 0.88 MAPT (0.70) HPSEMMP2MMP9MMP8MMP13

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023203161-A1 COMPOUNDS INDUCING PRODUCTION OF PROTEINS BY IMMUNE CELLS UNIVERSITE PARIS CITE (FR) 2023-10-26 WO disclosed
EP-4265246-A1 COMPOUNDS INDUCING PRODUCTION OF PROTEINS BY IMMUNE CELLS Université Paris Cité (FR) 2023-10-25 EP disclosed
US-9622991-B2 Hematopoietic growth factor mimetic small molecule compounds and their uses LIGAND PHARMACEUTICALS INC. (US) 2017-04-18 US disclosed
US-9622991-B2 Hematopoietic growth factor mimetic small molecule compounds and their uses LIGAND PHARMACEUTICALS INC. (US) 2017-04-18 US disclosed
US-9144557-B2 Hematopoietic growth factor mimetic small molecule compounds and their uses LIGAND PHARMACEUTICALS INC. (US) 2015-09-29 US disclosed
US-9144557-B2 Hematopoietic growth factor mimetic small molecule compounds and their uses LIGAND PHARMACEUTICALS INC. (US) 2015-09-29 US disclosed
US-20150252043-A1 HEMATOPOIETIC GROWTH FACTOR MIMETIC SMALL MOLECULE COMPOUNDS AND THEIR USES CITIBANK, N.A., AS ADMINISTRATIVE AGENT 2015-09-10 US disclosed
US-20150252043-A1 HEMATOPOIETIC GROWTH FACTOR MIMETIC SMALL MOLECULE COMPOUNDS AND THEIR USES CITIBANK, N.A., AS ADMINISTRATIVE AGENT 2015-09-10 US disclosed
US-20140243324-A1 USE OF HEMATOPOIETIC GROWTH FACTOR MIMETICS LIGAND PHARMACEUTICALS INCORPORATED (US) 2014-08-28 US disclosed
US-20140243324-A1 USE OF HEMATOPOIETIC GROWTH FACTOR MIMETICS LIGAND PHARMACEUTICALS INCORPORATED (US) 2014-08-28 US disclosed
US-20120295904-A1 HEMATOPOIETIC GROWTH FACTOR MIMETIC SMALL MOLECULE COMPOUNDS AND THEIR USES LIGAND PHARMACEUTICALS INC. (US) 2012-11-22 US disclosed
US-20120295904-A1 HEMATOPOIETIC GROWTH FACTOR MIMETIC SMALL MOLECULE COMPOUNDS AND THEIR USES LIGAND PHARMACEUTICALS INC. (US) 2012-11-22 US disclosed
WO-2012068406-A2 USE OF HEMATOPOIETIC GROWTH FACTOR MIMETICS LIGAND PHARMACEUTICALS INCORPORATED (US) 2012-05-24 WO disclosed
WO-2011046954-A1 HEMATOPOIETIC GROWTH FACTOR MIMETIC SMALL MOLECULE COMPOUNDS AND THEIR USES LIGAND PHARMACEUTICALS INC. (US) 2011-04-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140243324-A1 USE OF HEMATOPOIETIC GROWTH FACTOR MIMETICS HGF, EPOR, MPL HPSE 354/4885MMP2 2911/4885MMP9 4364/4885
US-20150252043-A1 HEMATOPOIETIC GROWTH FACTOR MIMETIC SMALL MOLECULE COMPOUNDS AND THEIR USES MPL, CSF3R, HGF HPSE 635/4885MMP2 3334/4885MMP9 3464/4885
US-20120295904-A1 HEMATOPOIETIC GROWTH FACTOR MIMETIC SMALL MOLECULE COMPOUNDS AND THEIR USES MPL, CSF3R, HGF HPSE 635/4885MMP2 3334/4885MMP9 3464/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.